“…MicroRNAs are now established therapeutically viable targets in the regulation of vascular inflammation and senescence (e.g., miR-146a, miR-217, miR-34a, miR-126, miR-21, miR-210, miR-181b) (121,151,169,170), tumor angiogenesis (miR-19b-1) (191), and in vascular diseases such as hypertension (miR-125a/b-5p) (83) and atherosclerosis (miR-92a, miR-27, miR-10a) (23, 46,47). In view of the established roles for TM in the regulation of inflammatory and thrombotic processes within the vascular wall, in conjunction with its indirect regulation by miR-92a via KLF2 (46,187), one can anticipate future studies detailing approaches to modulating TM levels in vivo using miRNA-targeting strategies.…”